ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial

Qu, Jinglei; He, Xin; Luo, Ying; Yu, Ping; Chen, Ying; Liu, Jing; Wang, Xin; Wang, Chang; Liang, Tingting; Bai, Yuxian; Han, Yu; Man, Li; Leng, Chuanchun; Zhou, Caiyun; He, Lijie; Liu, Yunpeng*; Qu, Xiujuan*吉林大学; 哈尔滨医科大学; 中国医科大学; 1
Frontiers in Oncology2023-4-24DOI: 10.3389/fonc.2023.1072943
16阅读
引用收藏
分享

摘要

ObjectiveApatinib and irinotecan are used as systematic therapies for advanced gastric adenocarcinoma (GAC) and gastroesophageal junction adenocarcinoma (GEJA), while the evidence for their combination as second-line therapy in these patients is limited. This study aimed to evaluate the efficacy and safety of second-line apatinib plus irinotecan for the treatment of GAC and GEJA. MethodsIn this prospective, multicenter phase II clinical study, 28 patients with advanced GAC or GEJA who received second-line apatinib plus irinotecan were recruited. ResultsIn total, 1 (3.6%) patient achieved complete response, 7 (25.0%) patients achieved partial response, 13 (46.4%) patients had stable disease, and 4 (14.3%) patients showed progressive disease, while clinical response was not evaluable or not assessed in 3 (10.7%) patients. The objective response rate and disease control rate were 28.6% and 75.0%, respectively. Meanwhile, the median (95% confidence interval (CI)) progression-free survival (PFS) was 4.5 (3.9-5.1) months, and the median (95% CI) overall survival (OS) was 11.3 (7.4-15.1) months. By multivariate Cox regression analysis, male sex, liver metastasis, and peritoneal metastasis were independently associated with worse PFS or OS, while treatment duration >= 5 months was independently associated with better OS. In terms of the safety profile, 89.3% of patients experienced treatment-emergent adverse events of any grade, among which 82.1% of patients had grade 1-2 adverse events and 64.3% of patients had grade 3-4 adverse events. ConclusionApatinib plus irinotecan as second-line therapy achieves a good treatment response and satisfactory survival with tolerable safety in patients with advanced GAC or GEJA.

学科与关键词

关键词
second-line apatinib plus irinotecangastric adenocarcinomagastroesophageal junction adenocarcinomatreatment efficacysafety
相关
加载中…
  • Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study
    Li, Jin; Qin, Shukui*; Wen, Lu; Wang, Junsheng; Deng, Wenying; Guo, Weijian; Jia, Tongfu; Jiang, Da; Zhang, Guifang; He, Yifu; Ba, Yi; Zhong, Haijun; Wang, Lin; Lin, Xiaoyan; Yang, Jianwei; Zhao, Jun; Bai, Yuxian; Wu, Xiangyuan; Gao, Feng; Sun, Guogui; Wu, Yongjuan; Ye, Feng; Wang, Qiong; Xie, Zhong; Yi, Tienan; Huang, Yong; Yu, Guohua; Lu, Lin; Yuan, Ying; Li, Wei; Liu, Likun; Sun, Yuping; Sun, Ying; Yin, Lifeng; Hou, ZhiguoBMC Medicine, 2023, 21(1): 173.被引 1
  • Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma
    Wang, Yonggang; Wang, Chang; Zhang, Yanqiao; Hao, Jiqing; Yang, Nong; Wang, Jvfeng; Peng, Min; Liu, Tianshu; Zhang, Guifang; Zhan, Xianbao; Zeng, Shan; Zhang, Yifan; Gao, Yong*; Yao, Yang*Frontiers in Oncology, 2022, 12: 876899.被引 1
  • The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
    Tang, Lin-Quan; Li, Xiao-Yun; Li, Zhi-Ming; Liu, Zhi-Gang; Lin, Miao-Zhen; Zhou, Huan; Yu, Qi-Wen; Zhou, Jian; Zhao, Chong; Chen, Ze-Bin; Wang, Xi-Cheng; Peng, Jia-Yu; Chen, Qiu-Yan; Fang, Wen-Feng; Yang, Yun-Peng; Zhang, Bei; Xia, Liang-Ping; Hu, Pi-Li; Hu, Wei-Han; Li, Yi-Jie; Mai, Hai-Qiang; Cai, Xiu-Yu*BMC Medicine, 2023, 21(1): 94.
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2023-04-24
卷期
第 13 卷
页码
1072943
DOI
10.3389/fonc.2023.1072943
成果收录
SCIE

作者

  • Q

    Qu, Jinglei (第一作者)

    1 · china med univ

  • H

    He, Xin

    1 · china med univ

查看全部 17 位作者收起作者
  • L

    Luo, Ying

    1 · china med univ

  • Y

    Yu, Ping

    1 · china med univ

  • C

    Chen, Ying

    1 · china med univ

  • L

    Liu, Jing

    china med univ

  • W

    Wang, Xin

    1 · china med univ

  • W

    Wang, Chang

    jilin univ

  • L

    Liang, Tingting

    jilin univ

  • B

    Bai, Yuxian

    harbin med univ

  • H

    Han, Yu

    harbin med univ

  • M

    Man, Li

  • L

    Leng, Chuanchun

  • Z

    Zhou, Caiyun

  • H

    He, Lijie

    peoples hosp liaoning prov

  • L

    Liu, Yunpeng (通讯)

    1 · china med univ

  • Q

    Qu, Xiujuan (通讯)

    1 · china med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417